BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Simply Wall St Article

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company focused on the development of drug products for patients with high unmet medical need conditions or no alternative treatment options, was featured in a Simply Wall St article. The piece highlights PCSA Co-Founder Patrick Lin’s recent stock purchase at near current price. The article reads, “Potential Processa Pharmaceuticals Inc. (NASDAQ: PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share. While that’s a very decent purchase to our minds, it was proportionally a bit modest, boosting their holding by just 8.5%. In fact, the recent purchase by Patrick Lin was the biggest purchase of Processa Pharmaceuticals shares made by an insider individual in the last twelve months, according to our records. That means that an insider was happy to buy shares at around the current price of US$4.08. . . . While we always like to see insider buying, it’s less meaningful if the purchases were made at much lower prices, as the opportunity they saw may have passed. Happily, the Processa Pharmaceuticals insiders decided to buy shares at close to current prices.”

To view Simply Wall St’s latest analysis for Processa Pharmaceuticals, visit https://ibn.fm/FRRP9

To view the full article, visit https://ibn.fm/IXeAR

About Processa Pharmaceuticals Inc.

The mission of Processa has been to develop products where existing clinical evidence of efficacy already exists in unmet medical need conditions — medical conditions where patients need treatment options that will improve survival and/or quality of life. The company has assembled a proven regulatory science development team, management team and board of directors. The Processa development team has been involved with more than 30 drug approvals by the FDA (including drug products targeted to orphan disease conditions) and 100 FDA meetings. For more information, visit the company’s website at www.ProcessaPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to PCSA are available in the company’s newsroom at https://ibn.fm/PCSA

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork